Neuroglee Therapeutics

What Neuroglee Therapeutics does

Neuroglee Therapeutics is a digital therapeutics company founded in 2020 that delivers comprehensive, clinically validated care for patients with mild cognitive impairment (MCI), Alzheimer's disease, and other dementias. The company's core product is Neuroglee Connect™, a digital therapeutics platform co-developed with the Mayo Clinic's HABIT (Healthy Actions to Benefit Independence & Thinking) program, which delivers personalized cognitive care plans, remote monitoring, cognitive exercises, and care partner support through a mobile application. The platform is paired with a physician-led, 24/7 interdisciplinary care team (care navigators, clinicians, licensed social workers, pharmacists) that delivers whole-person clinical support between primary care and neurology visits.

Neuroglee operates a B2B2C business model with three primary customer segments: Medicare Advantage and other health plans seeking to reduce total cost of care for dementia populations (claimed $2,600+ PMPY savings against $6,500+ baseline Medicare dementia costs), primary care organizations operating under MSSP/ACO Reach value-based contracts, and neurology groups extending their care capacity. As an official CMS GUIDE (Guiding an Improved Dementia Experience) Model participant since July 1, 2024, Neuroglee delivers Medicare-funded comprehensive dementia care including up to $2,500/year per patient in respite services. Revenue streams combine value-based care arrangements (risk-bearing or shared-savings contracts), CMS GUIDE reimbursement, and a separate quarterly/annual membership subscription fee for non-insurance-covered digital tools and health coach services.

The company is incorporated in the United States as Neuroglee Therapeutics, Inc. and operates from Boston, MA. It has raised $12.3 million in disclosed funding across a 2020 seed round (Eisai, $2.3M) and a September 2021 Series A ($10M, led by Openspace Ventures and EDBI). The platform holds SOC 2 Type II and HIPAA certifications, and the company maintains affiliated clinical entities (Neuroglee Care, PLLC; Independent Care Medical PLLC) that deliver in-scope clinical services. The product roadmap extends beyond Alzheimer's into Parkinson's disease and stroke recovery therapeutics.

Name

Neuroglee Therapeutics

Legal name

Neuroglee Therapeutics, Inc.

Website

https://neuroglee.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Neuroglee Therapeutics is a digital therapeutics company delivering comprehensive dementia and memory care through its Mayo Clinic–partnered Neuroglee Connect™ platform and 24/7 physician-led care team, serving Medicare patients and value-based contracts with health plans, primary care groups, and neurology practices.

Ownership category

akta.pro rank

Product category

Digital Therapeutics for Dementia and Cognitive Care

NAICS

Services for the Elderly and Persons with Disabilities (624120), Services for the Elderly and Persons with Disabilities (62412), Other Individual and Family Services (624190)

SIC

Services-Health Services (8000), Services-Home Health Care Services (8082), Services-Prepackaged Software (7372)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Memory Care Care Management & Navigation (Dementia Care Coordination) (HLADACAJ), Neurology Telemedicine Platforms (HLALAGAC), Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK)

Keywords

• Digital therapeutics
• Dementia care platform
• Value-based dementia care
• Remote cognitive monitoring
• CMS GUIDE program

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Value-Based Care Arrangements with Health Plans: Neuroglee partners with Medicare Advantage and other health plans under value-based care contracts, earning revenue based on demonstrated cost savings and outcomes improvement for their dementia populations. The company highlights $2,600+ per member per year savings opportunity for plans.
2. Value-Based Partnerships with Provider Groups: Revenue from partnerships with primary care and neurology organizations under risk-based or shared savings arrangements. Neuroglee structures payment arrangements with primary care partners that protect downside risk, supporting performance in MSSP and ACO Reach programs.
3. CMS GUIDE Program: As an official GUIDE Model participant, Neuroglee delivers CMS-funded comprehensive dementia care including respite services up to $2,500/year per patient. Revenue is supported by CMS reimbursement for GUIDE care delivery requirements.
4. Telehealth / Subscription Membership Fee: Neuroglee charges a membership subscription fee for access to certain platform features, technology, virtual visits with health coaches, and digital tools not covered by insurance. This fee is billed quarterly or annually and is separate from insurance-billed services.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Neuroglee Therapeutics operates a digital therapeutics platform, Neuroglee Connect™, developed in partnership with the Mayo Clinic, that delivers clinically proven cognitive interventions for patients with mild cognitive impairment and early-stage dementia. The platform combines machine learning, digital biomarkers, remote monitoring, and a 24/7 physician-led interdisciplinary care team, delivered through a mobile and web application to patients referred by health plans, primary care groups, and neurology practices under value-based care arrangements including the CMS GUIDE Model.

Product overview

Neuroglee Therapeutics operates as a digital health company offering a unified care platform centered on Neuroglee Connect™ — a Mayo Clinic partnership-developed digital solution — combined with a 24/7 physician-led interdisciplinary care team. The platform is delivered through a mobile/desktop application and integrates remote monitoring, cognitive exercises, and machine learning-driven personalization. As an official CMS GUIDE Model participant, Neuroglee also delivers a comprehensive dementia care program at no cost to Medicare patients, wrapping in medication management, caregiver support, and respite services. The product portfolio spans a digital therapeutics platform (using ML and digital biomarkers for neurodegenerative diseases including Alzheimer's, Parkinson's, and stroke recovery), the Neuroglee Connect™ HABIT solution for early-stage cognitive impairment, and ongoing clinic and virtual neurology expansion.

Differentiator

Problem solved

Functional benefit

Brands

• Neuroglee Connect: Digital platform developed in partnership with Mayo Clinic's HABIT program providing clinically proven solutions for patients with mild cognitive impairment and early-stage memory loss.

Products and services

• Neuroglee Connect™ A digital therapeutics platform developed in partnership with the Mayo Clinic's HABIT program that provides clinically proven cognitive interventions for patients with mild cognitive impairment and early-stage dementia. Delivered through a mobile and web application with 24/7 access to a care team, personalized cognitive care plans, remote monitoring, and care partner support.
• Neuroglee Care Team A physician-led interdisciplinary clinical service providing 24/7 access to dementia-trained professionals including care navigators, clinicians, social workers, and pharmacists. The team delivers personalized clinical support, symptom management, medication management, and care coordination for patients with MCI and dementia and their care partners.
• CMS GUIDE Program An 8-year CMS-funded Medicare program (launched July 1, 2024) providing comprehensive dementia care at no cost to eligible Medicare patients. Includes comprehensive assessments, personalized care plans, medication management, 24/7 care team access, care coordination, caregiver education and support, and up to $2,500/year in respite care services.

Quantifiable outcome

• 96% of Neuroglee patients report being highly satisfied with their experience
• +6 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Centers for Medicare & Medicaid Services (CMS)coreStrategic or Co-development Partner · 1 July 2024Neuroglee is an official participant in the CMS GUIDE (Guiding an Improved Dementia Experience) Model, an 8-year Medicare initiative launched July 1, 2024 providing comprehensive dementia care at no cost to eligible patients. Neuroglee delivers all nine required care delivery components including respite care up to $2,500/year per patient.
• Mayo CliniccoreStrategic or Co-development PartnerNeuroglee's most significant clinical partnership is with the Mayo Clinic, specifically the HABIT (Healthy Actions to Benefit Independence & Thinking) program. This partnership resulted in Neuroglee Connect HABIT, the only clinically proven solution that improves independence, functional abilities, self-efficacy, and quality of life for patients with early memory loss. Mayo Clinic's logo appears prominently on Neuroglee's homepage as a featured partner, signaling deep clinical validation.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Linus Health: Linus Health is a digital cognitive assessment and brain health platform focused on early detection of dementia and other cognitive conditions, serving health plans and providers with a value-based, evidence-based model similar to Neuroglee's positioning.
• BrainCheck: BrainCheck provides digital cognitive assessment and care planning tools for clinicians managing patients with MCI and dementia, directly competing in the same physician-facing cognitive care workflow that Neuroglee Connect targets.
• Click Therapeutics: Click Therapeutics develops and commercializes prescription digital therapeutics across multiple indications, sharing Neuroglee's DTx platform-plus-clinical-validation business model and pharma partnership approach.
• Akili Interactive (Virtual Therapeutics): Akili Interactive (now Virtual Therapeutics) is a pioneering prescription digital therapeutic company that built and commercialized FDA-cleared DTx products, comparable to Neuroglee as a clinically validated, regulated digital therapeutics peer.

Emerging players

• Altoida: Altoida develops digital biomarkers and AI-driven cognitive assessment tools aimed at early Alzheimer's detection, overlapping with Neuroglee's neurodegenerative digital therapeutic focus on MCI and early dementia.
• Cognito Therapeutics: Cognito Therapeutics is developing a prescription digital therapeutic for Alzheimer's disease using sensory stimulation, competing with Neuroglee in the prescription-grade digital therapeutics category for neurodegenerative disease.
• Big Health: Big Health builds digital therapeutics for mental health conditions (insomnia, anxiety) delivered via partnerships with health plans and employers, sharing Neuroglee's payer-facing DTx distribution model though targeting different indications.
• Constant Therapy Health: Constant Therapy Health provides a digital therapy platform for cognitive, speech, and language rehabilitation, with overlap to Neuroglee in clinician-prescribed digital cognitive rehabilitation for neurological conditions.

Broad incumbents

• Eisai (digital initiatives): Eisai is a global pharmaceutical company focused on Alzheimer's and dementia treatments that also participated in Neuroglee's funding; its broader digital and disease-management initiatives are thematically comparable to Neuroglee's neurodegenerative DTx strategy.
• Eli Lilly (Lilly Health): Eli Lilly is investing heavily in Alzheimer's therapeutics (e.g., Kisunla, donanemab) and related digital patient support infrastructure, making it a broad incumbent whose dementia strategy increasingly intersects with Neuroglee's value-based care positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neuroglee-therapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuroglee Therapeutics